The Math Behind Deposit Insurance, And Why It's The Beginning Of The End
As Simon White writes today, "a full guarantee of all bank deposits would spell the end of moral hazard disciplining banks and mark the final chapter of the dollar’s multi-decade debasement." And yet that's where we are headed, even if with a few hiccups along the way, because as White also notes, with the latest banking crisis in the US, it’s the clean-up that could end up doing far more lasting damage. That's because with the failure of SVB et al prompted the FDIC to guarantee that all depositors will be made whole, whether insured or not
And so, the precedent is being set, with Treasury Secretary Janet Yellen commenting on Tuesday that the US could repeat its actions if other banks became imperiled. She was referring to smaller lenders, and denied the next day that insurance would be “blanket”, but given the regulatory direction of travel over the last forty years, this will inevitability apply to any lender when push comes to shove.
Realizing it's just a matter of time before the next systemic crisis tips the banking sector over, over the weekend, a coalition of midsize US banks asked federal regulators to extend FDIC deposit insurance for the next two years, so as to alleviate any fears which could result in a wider deposit run on regional and community banks.
But what would deposit insurance of all $18 trillion US deposits - not just the $11 or so trillion in deposits that are currently "insured" by the FDIC - look like? As BofA's rates strategist Mark Cabana writes, deposit insurance has been a very effective solution to stabilize deposit outflows historically. Deposit insurance can be done in a variety of ways: (1) all domestic bank deposits; (2) increase coverage to a higher amount vs. the $250k currently.
If policymakers consider extending deposit insurance coverage it would impact reserves held in the Deposit Insurance Fund (DIF).
What is DIF? One way the FDIC maintains stability and public confidence in the U.S. financial system is by providing deposit insurance. The primary purposes of the Deposit Insurance Fund (DIF) are:
to insure the deposits and protect the depositors of insured banks and
to resolve failed banks.
While the DIF is backed by the full faith and credit of the United States government, it has two sources of funds: i) assessments (insurance premiums) on FDIC-insured institutions and ii) interest earned on funds invested in U.S. government obligations. The government guarantee of insured deposits is not limited by the amount in the DIF. One can think of DIF as a "first loss" tranche absorbed by assessed bank funds in DIF.
Where does the DIF stand today? The DIF's reserve ratio (the fund balance as a percent of insured deposits) was 1.27% (or $128.2bn) on Dec 31, 2022. The FDIC was aiming to increase the reserve ratio to 1.35% by Sep 30, 2028 or ~$8bn increase.
What % of deposits are insured? Estimated insured deposits stood at $10.1 trillion or 56.8% of total deposits held at FDIC insured institutions of $17.8trn as of Dec 31, 2022. Recent proposals would increase insurance coverage; the extent of insurance increase differs by proposal.
DIF increase needed to provide more insurance? Assuming the 1.35% target reserve ratio is applied to the uninsured deposits, this would imply a reserve build of $104bn.
Cost to insure all deposits? $104bn in reserve build to cover uninsured deposits compares to net income across all FDIC insured banks of $263bn reported for 2022. Obviously, this reserve build would need to happen over several years to limit the impact on industry profitability in any given year. Assuming that this additional assessment is spread over ten years, implies an approximately 50bp drag on annual ROE for the industry.
Of course, all this assumes the DIF is never really used, but the statutory amount is meant to serve as a confidence booster. After all, the total expanded DIF amount of $230 billion would be insufficient to bail out the uninsured depositors of even one TBTF bank like JPM. In fact, if all deposit insurance had to be used, it would mean the US government somehow has to fund a total of $18 trillion in deposits, an amount equal to 75% of US GDP. It's ain't happening.
Is any of this a viable option? While we are skeptical confidence can be restored with some accounting sleight of hand, Mark Cabana is optimistic and sees deposit insurance as one way for policymakers and the banking industry to address sensitivity among deposit customers. Absent such broader insurance, the industry risks losing some deposits to money market funds or the Treasury market as customers diversify their excess liquidity.
Cabana's conclusion:
We believe that the last few days have introduced investors/ banks/ policymakers to the new risk of deposit-runs in the age of social media. We believe that absent a change to deposit insurance coverage, corporate CFOs/Treasurers will likely be proactively looking to diversify their deposits away from any single institution. While this may be viewed as a reasonable outcome by some, regional banks could be at the losing end under such a scenario. If maintaining the community banking structure is a priority for policymakers, a higher threshold of deposit insurance seems worth considering.
Alas, if Janet Yellen is to be believed, this isn't on the horizon, at least not until we have another sharp deterioration in the banking crisis.
Stepping back from the accounting intricacies of how the US can backstop the impossible sum of $18 trillion without actually doing so - because it's simply impossible - and turning to the bigger picture implications, we go back to BBG's Simon White who notes that since the dollar is the primary liability of the US central bank; "this would mean further erosion of its real value, compounding the decimation of its purchasing power seen over the last century."
But why is deposit insurance linked to the strength of the dollar... and by extension its persistence as world reserve currency? Simple: it all has to do with that ultimate backstopper of the US financial system (where deposits are the largest liability) and the assets on its balance sheet. Here are some more observations from White:
The 1932 Glass-Stegall Act was the beginning of the end, allowing the Fed to accept a wider basket of collateral it could lend against: riskier assets such as longer-term Treasury securities. The falling quality of collateral has continued, with the Fed lending against corporate debt in recent years
The end result is the Fed’s balance sheet has steadily deteriorated, and with it the real value of the dollar
Obviously, then, an expansion of insurance to all deposits will lead to a further erosion in the Fed’s balance sheet. Why?
First: deposit-insurance schemes typically lead to less, not more, bank stability. Several studies have shown that countries with deposit-insurance schemes tend to see more bank failures. The more generous the scheme, the greater the instability.
Second: Moral hazard instills discipline in depositors as they pay attention to the bank’s credit risk (something many depositors in SVB signally failed to do.) It also imposes discipline on banks, incentivizing them to structure their cash flows so that they match through all time, thus mitigating the risk of bank runs (cue SVB again)
Why, then, would greater banking instability lead to a further deterioration in the Fed’s balance sheet? It comes down to how US banking has evolved over the last century.
Banks must manage cash flows from assets and liabilities, and their preference is to minimize their cash position each night in order to maximize the productive use of their capital. There is always a “position making” instrument, a liquid asset that banks can use to park excess cash or make up for shortfalls each day. In the early days of the Federal Reserve system it was commercial loans and USTs; now it is principally the repo market. A bank can “make position” if it can repo in or repo out securities for funds. But if the market for that collateral freezes up, they’re dead.
This is where the Fed steps in - but as the “dealer of last resort” rather than the lender of last resort. To ensure market liquidity, the Fed must underwrite funding liquidity. And to do that it must be willing to accept as collateral whatever the banking sector’s position-making instruments are.
If it doesn’t, the game’s up.
SVB happened to have a high proportion of USTs and mortgage-backed securities on its balance sheet, making the Fed’s life easy in creating the BTFP (Bank Term Funding Program), which accepts government and government-backed collateral. But this does not get to the heart of the problem. Only a fifth of small banks’ assets are currently shiftable on to the Fed’s balance - less than for larger lenders — leaving them considerably exposed!
Ultimately, deposit insurance only mitigates banks’ vulnerability to bank runs; it does not insulate them from liquidity or insolvency risk; and it certainly does not "insure" that a full-scale bank run will see every depositors' money made whole: after all there is just $128BN in the DIF and there are $10 trillion in insured deposits. At best, the DIF provides a first loss backstop only to those who panic first!
But the punchline is that SVB et al are very likely not the only fragile US banks, and as the economy slows, asset prices fall and delinquencies and bankruptcies rise - especially in commercial real estate, where small banks also happen to be the biggest lenders - we are likely to see more banks needing support
The logical outcome is that the Fed will have to increasingly accept poorer quality collateral — especially from smaller banks, with their large exposure to residential and commercial real estate. We have been here before, when during the pandemic the Fed began to accept the corporate debt of even junk-rated companies (and when gold and bitcoin hit record highs).
Minsky himself stressed the centrality of banking to financial stability, noting that imprudent banks (read: operating without moral hazard) are more likely to finance unproductive projects, which then leads to inflation.
So there we have it. As White concludes, after the US inevitably implements deposit insurance, what comes next is inflation and much more debasement of the Fed’s balance sheet: "with an abnegation of moral hazard, the long-term value of the dollar doesn’t stand a chance."
Which is also why US authorities are doing everything in their power to rapidly kill-off such counterparty-free money as bitcoin and gold, with headlines such as these now a daily occurrence:
U.S. SECURITIES AND EXCHANGE COMMISSION ISSUES INVESTOR ALERT URGING CAUTION AROUND CRYPTO ASSET SECURITIES
...they know very well that during the next crisis - which is imminent - the monetary tidal wave will flow toward them as the bank failure dominoes begin to fall.
The US Non-Farm Payroll jobs report due on Friday is the key data point of the coming week.
Analysts predict payrolls will fall to 150,000 from 187,000 last month and the unemployment rate to hold at 3.8%.
Average hourly earnings are expected to increase 0.3% month-on-month.
Any deviation from those forecasts can be expected to trigger price moves in all the major currency markets.
US dollar strength continues to be the underlying theme of the currency markets, with EURUSD currently testing the key 1.04823 support level and the GBPUSD downward price channel showing few signs of reversing. The US Non-Farm Payrolls jobs report, due to be released on Friday, is always an important milestone in the trading month, and September’s numbers could offer clues as to how far the current trend has left to run.
US Dollar
The Non-Farm Payrolls employment report, released on the first Friday of every month, often sets the tone for the following week’s trading. After this September, which saw EURUSD and GBPUSD give up 2.48% and 3.70% in value, respectively, Friday’s report is the most important item on the coming week’s economic calendar. The jobs report will be a crucial indicator of whether the rush to the dollar is likely to continue or if a reversal could be about to form.
ISM Purchasing and Services data will also offer an insight into the health of the US economy, and big corporations will kick off earnings season next week. There is also the backdrop of the US Federal budget and a possible government shutdown to consider, but for now, the NFP is the most likely catalyst of the next price moves.
Daily Price Chart – US Dollar Basket Index – Daily Price Chart – 20 SMA
Source: IG
EURUSD
The coming week is quiet in terms of euro-specific data releases, but updates from other regions look set to influence the value of euro-based currency pairs. Due on Friday, the NFP number out of the states will very likely impact prices in the largest currency market in the world – the Eurodollar. Before that, on Tuesday, the interest rate decision due to be announced by the Reserve Bank of Australia will influence EURAUD price levels. However, comments from that central bank can also be taken as a guide regarding the mood of the rest of the central bank peer group.
EURUSD has started the week trading midrange between two significant support and resistance price levels. To the downside is the 1.04823 support level, which marks the price low of 6th January. That still represents the current year-to-date low for EURUSD, but the tests of that level on Wednesday (1.04880) and Thursday (1.04910) suggest that bearish momentum is still strong.
Whilst the bounce off that level was strong enough for traders to think a trend reversal could be imminent, there is also resistance to further upward moves in the region of 1.06351. That price level relates to the swing-low price pattern formed on 31st May and previously acted as support between 14th and 25th September.
GBPUSD
As with the euro, traders of sterling-based currency pairs will see prices influenced by announcements from other regions rather than UK authorities this week. The run-up to the release of the NFP jobs report could see GBPUSD continue to trade within a range formed by key support/resistance price levels.
Price level 1.23081 marks the upper end of the current price channel and is the low price recorded during the swing-low price move of 25th May. This level didn’t offer as much support as expected when it was breached on 21st September, and with the RSI on the Daily Price Chart at 29.09, there are signs the market is oversold and is due a bounce.
Daily Price Chart – GBPUSD – Daily Price Chart
Source: IG
The downward trend, which started on 13th July, has formed a price channel which has trendlines which have been barely tested over a period of weeks. That leaves plenty of room for the price of GBPUSD to continue to weaken and move towards the major support level of 1.18030, which marks the year-to-date price low of 8th March.
USDJPY
The recent decision by the Bank of Japan to continue with its dovish approach to interest rates has left room for USDJPY to track upwards, guided by the 20 SMA on the Daily Price Chart. That metric remains the key indicator, and until price breaks through that level (currently 148.21), there is room for a test of the multi-year price high 151.946 printed on 21st October 2022.
Daily Price Chart – USDJPY – Daily Price Chart
Source: IG
Monday sees the Japan Tankan Index number for Q3 be released. Analysts forecast that the index will rise to 7, but as with the other major currency pairs, the major news event of the week is the NFP employment report due on Friday.
77% of CFD traders lose Founded: 2007 77 % of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
Risk Statement: Trading financial products carries a high risk to your capital, especially trading leverage products such as CFDs. They may not be suitable for everyone. Please make sure that you fully understand the risks. You should consider whether you can afford to take the risk of losing your money.
Bonds, Bullion, & Black Gold Battered As Hawkish FedSpeak & Inflation Fears Lift The Dollar
Rate-change expectations shifted hawkishly today, after drifting dovishly for the last week, on the heels of the Manufacturing PMI's report which showed the rate of inflation quickened to the sharpest pace in five months and FedSpeak which confirmed Powell's "higher for longer" messaging.
Source: Bloomberg
In the US, S&P Global noted
“Less encouraging was the news on the inflation outlook, as producers’ costs rose at the fastest rate for five months, largely on the back of higher oil prices. These increased costs are already feeding through to higher prices to customers, which will inevitably result in some renewed upward pressure on inflation.”
Globally, JPMorgan warned that there were further signs of price pressures building in September.
Input costs and output charges both rose for the second consecutive months, with rates of inflation accelerating for both measures.
Fed Gov Michelle Bowman again said that multiple interest-rate hikes may be required to get inflation down:
“I continue to expect that further rate increases will likely be needed to return inflation to 2% in a timely way,” Bowman said in remarks prepared for delivery to bankers in Banff, Canada.
“I see a continued risk that high energy prices could reverse some of the progress we have seen on inflation in recent months.”
Fed Vice Chair Michael Barr said the US central bank is “likely at or very near” a level of interest rates that is sufficiently restrictive:
“I think it is likely that we’ll need to keep rates up for some time in order to get inflation down to 2%. I’m confident that we’ll get there.”
Traders were buying protection against a less-hawkish Fed. Bloomberg notes significant SOFR flows on the day have been skewed toward dovish protection into year-end, standing to benefit from no more additional rate hikes from the Fed.
The hawkish shift sent the dollar higher, rallying back up to perfectly tag the stops from Wednesday highs...
Source: Bloomberg
The stronger dollar weighed on crude oil prices, with WTI sliding back below $89, as Citi's Ed Morse muttered something about Oil "going back to the $70s" as “demand looks constrained as the pandemic recovery factors continue to ease off and peak transport fuel demand looms, while supply is growing in non-OPEC+ suppliers”
And gold was dumped to fresh cycle lows, selling off for the 6th day in a row (9th drop in the last 10 days)...
Source: Bloomberg
Spot Platinum prices plunged to their lowest since Oct 2022...
Source: Bloomberg
Treasuries were sold across the board with the belly (5s-10s) suffering the most...
Source: Bloomberg
Which steepened the yield curve (2s10s) to its least-inverted since the peak of the SVB crisis...
Source: Bloomberg
Bitcoin continued to drift higher, spiking above $28,500 intraday
Source: Bloomberg
Stocks were very mixed on the day with Small Caps clubbed like a baby seal while Mega-Cap tech outperformed leave The Dow and S&P trying to get back above water...
Value stocks puked relative to Growth, erasing their recent gains...
Source: Bloomberg
'Most shorted' stocks were hammered for the second day in a row with no squeeze attempts...
Source: Bloomberg
Utes were the biggest losers today (NEE's plunge did not help) and Tech stocks were the only sector to end green...
Source: Bloomberg
That's quite a puke in Utes...
Source: Bloomberg
Goldman's data could hint at capitulative flows: CTAs as short $17.8bn of global equities (31st %tile), while In the US, CTAs are short $17.5bn of equities after selling -$59bn over the last two weeks, representing the largest two week selling since Covid!
After a massive $59BN in selling in past 2 weeks (as noted two weeks ago), systematics have fully liquidated. CTAs are all uphill from here.
Also dealer gamma almost back to positive after hitting record negative last week.
Soon after he joined UC Riverside in 2015, Maurizio Pellecchia, a professor of biomedical sciences in the UCR School of Medicine, began working with the UCR Research and Economic Development office to create on campus an incubator space. He envisioned that space as a home for UCR scientists to create startup companies to prove the commercial potential of their technologies. That multi-year effort helped create in the Multidisciplinary Research Building the EPIC Life Sciences Incubator that currently houses young companies in agricultural technology, biomedical technologies, bioengineering, and medicinal chemistry.
Credit: Stan Lim, UC Riverside.
Soon after he joined UC Riverside in 2015, Maurizio Pellecchia, a professor of biomedical sciences in the UCR School of Medicine, began working with the UCR Research and Economic Development office to create on campus an incubator space. He envisioned that space as a home for UCR scientists to create startup companies to prove the commercial potential of their technologies. That multi-year effort helped create in the Multidisciplinary Research Building the EPIC Life Sciences Incubator that currently houses young companies in agricultural technology, biomedical technologies, bioengineering, and medicinal chemistry.
One of the tenant companies in the incubator space is Armida Labs, Inc, a pharmaceutical company founded two years ago by Pellecchia with Carlo Baggio, formerly a senior scientist in Pellecchia’s research group, as its chief technology officer and director of chemical biology. Armida Labs, which is developing a breakthrough pancreatic cancer therapy called Targefrin™, has now been awarded a highly competitive $400,000 Phase I Small Business Innovation Research, or SBIR, grant from the National Cancer Institute of the National Institutes of Health. The grant, of which Baggio is principal investigator, will allow the company to complete important next steps toward the preparation of human clinical trials.
“Our goal is to develop the drug Targefrin, which UCR has patented,” said Pellecchia, who holds the Daniel Hays Chair in Cancer Research at UCR. “We want to translate Targefrin from a laboratory discovery to a product that can fight pancreatic cancer, and potentially other cancers, and improve public health.”
Pellecchia, who is the main inventor of Targefrin, explained that the SBIR grant makes it possible for Armida Labs to gather industry-standard pharmacokinetics and efficacy data, which are expensive to obtain.
“Without the grant, our studies would remain at the pre-clinical level,” said Pellecchia, who directs the School of Medicine’s Center for Molecular and Translational Medicine. “The Phase I SBIR grant will allow us to scale up the manufacture of Targefrin and to test this drug in more sophisticated pharmacology studies in models of metastatic pancreatic cancer. These data will help us craft the necessary follow-up studies that will enable filing an investigational new drug application with the Food and Drug Administration, and if successful, begin human clinical studies.”
The SBIR grant Armida Labs received is a Phase I grant, which means it is a pilot phase grant. Only recipients of a Phase I grant can apply to the NIH for a Phase II grant.
“Phase II grants, which can be up to around $2 million, can allow us to apply for an IND,” Pellecchia said. “We expect our pilot studies will take about six months to one year to do. If these studies are successful, we will submit a Phase II application, which will allow us to complete toxicity studies in two animal models.”
An investigational new drug, or IND, is a drug that the Food and Drug Administration has not yet approved for general use. Researchers use INDs in clinical trials to investigate their safety and efficacy. Before testing in human subjects, however, researchers need to apply for an IND with the Food and Drug Administration.
According to Pellecchia, the EPIC Life Sciences Incubator greatly simplified the launch of Armida Labs, the first UCR faculty biopharmaceutical company in the City of Riverside. He said it is a lot easier to start a company in an incubator space than to have to rent an empty lab space somewhere to start doing research.
“Developing and growing a biotech company requires huge amounts of capital,” he said. “In contrast, a minimal amount of capital is needed to launch a startup in an incubator space. As a result, we were able to get Armida Labs off the ground and thus apply to the National Cancer Institute for seed funding. To go from a pre-clinical laboratory discovery all the way to drug development in patients, similar projects to Targefrin often require as much as $2-5 million. With our new award, we aim to complete valuable steps to attract further investment.”
The EPIC Life Sciences Incubator, which is managed by Maricela Argueta and directed by David Pearson, aims to be a home for startups like Armida Labs by providing vital technology and equipment, as well as access to UCR’s core technical facilities, faculty, and entrepreneurial development services from the Office of Technology Partnerships led by Associate Vice Chancellor Rosibel Ochoa. It offers advice, makes connections with venture capital firms, administers the incubator space, and provides personnel for coordinating the use of shared equipment.
Pellecchia is excited to have launched Armida Labs and acquired the SBIR grant. As the company grows, it will hire more personnel.
“Nothing would make me happier than to see our UCR research translated into experimental therapeutics. I am also thrilled to create new biotech jobs in Riverside, a region lacking incubator spaces where biotech companies can start and grow,” Pellecchia said. “At UCR, we graduate thousands of students and train many postdocs. But we are really educating and training them only to see them go elsewhere. We want them to stay and thrive in Riverside.”
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.